You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion alongside IPOPI at the IPIC Congress in Madrid

The importance of early diagnosis and the most recent innovations in the treatment of PID patients were the focus

read more 

EVENTS

Kedrion keeps Hemophilia therapy debate flowing in Latin America

A recent CLAHT Congress symposium restates current and future role of replacement therapy

read more 

CORPORATE

FSI SGR enters Kedrion share capital

The company continues with its growth and development strategy

read more 
  1. EVENTS - 09-11-2017

    Kedrion Biopharma joins IPOPI in supporting patients with APP PID Genius

    This new APP, presented at the IPIC Congress in Dubai, will be the personal assistant to people living with PIDs

    read more 
  2. CORPORATE - 31-10-2017

    Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy

    Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells

    read more 
  3. CORPORATE - 25-08-2017

    Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

    The product is approved for post-exposure prophylaxis against rabies infection

    read more 
  4. EVENTS - 14-07-2017

    Kedrion Biopharma attends XXVI ISTH Congress in Berlin, Germany

    A crowded symposium dedicated to the SIPPET Study was held on July 9th

    read more 

Pages

For more information please contact: pressoffice@kedrion.com